Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Cash (2020 - 2025)

Historic Change in Cash for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to -$25.6 million.

  • Arcutis Biotherapeutics' Change in Cash fell 15065.14% to -$25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.0 million, marking a year-over-year decrease of 42520.69%. This contributed to the annual value of -$17.4 million for FY2024, which is 15042.67% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Change in Cash of -$25.6 million as of Q3 2025, which was down 15065.14% from $19.3 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Change in Cash high stood at $223.6 million for Q1 2021, and its period low was -$199.6 million during Q2 2021.
  • Its 5-year average for Change in Cash is -$1.0 million, with a median of -$8.3 million in 2022.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 93148.81% in 2021, then surged by 204599.07% in 2024.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Change in Cash stood at $44.7 million in 2021, then crashed by 162.46% to -$27.9 million in 2022, then skyrocketed by 31.64% to -$19.1 million in 2023, then plummeted by 233.02% to -$63.5 million in 2024, then surged by 59.66% to -$25.6 million in 2025.
  • Its Change in Cash stands at -$25.6 million for Q3 2025, versus $19.3 million for Q2 2025 and -$18.2 million for Q1 2025.